TABLE 3.
Tumorigenicity of SCL LMO1 thymocytes in nude micea
| Cells injected (age [wks]) | Route | n | Tumors | Time inter-val (wks) |
|---|---|---|---|---|
| SCL LMO1 leukemic cells | s.c. | 1 | 1 | 3 |
| SCL LMO1 leukemic cells | i.p. | 2 | 2 | 3 |
| Normal thymocytes (12) | s.c. | 1 | 0 | >32 |
| Normal thymocytes (12) | i.p. | 1 | 0 | >32 |
| SCL LMO1 thymocytes (12) | s.c. | 2 | 0 | >32 |
| SCL LMO1 thymocytes (12) | i.p. | 2 | 2 | 3–7 |
| Normal thymocytes (8) | i.p. | 3 | 0 | >32 |
| SCL LMO1 thymocytes (8) | i.p. | 4 | 1 | 19 |
| Normal thymocytes (4) | i.p. | 2 | 0 | >32 |
| SCL LMO1 thymocytes (4) | i.p. | 4 | 0 | >32 |
a
Cells were injected by either the subcutaneous (s.c.) or the intraperitoneal (i.p.) route. Data under the heading n are numbers of mice that were injected; data under the heading Tumors are numbers of mice that developed T-cell tumors. Time intervals of 3 to 19 weeks refer to the time between the injection and tumor development; a period of “>32” weeks refers to mice observed for at least 32 weeks that did not develop disease.